---
title: Hormone replacement therapy and menopause
videoId: Dyid7vWO0zI
---

From: [[foundmyfitness]] <br/> 

Menopause marks a significant physiological transition in women, characterized by the decline and eventual cessation of three crucial hormones: estrogen, progesterone, and testosterone <a class="yt-timestamp" data-t="02:41:15">[02:41:15]</a>. This hormonal shift can be quite dramatic <a class="yt-timestamp" data-t="02:41:15">[02:41:15]</a>. While testosterone declines more gradually than estrogen and progesterone, which drop off sharply around menopause <a class="yt-timestamp" data-t="02:41:45">[02:41:45]</a>, it is still by far the most dominant hormone in terms of absolute amounts for both men and women <a class="yt-timestamp" data-t="02:39:41">[02:39:41]</a>.

## Symptoms of Menopause

The cessation of these hormones leads to a range of symptoms and long-term health consequences:
*   **Vasomotor Symptoms** The most commonly recognized symptoms are hot flashes and night sweats <a class="yt-timestamp" data-t="02:39:50">[02:39:50]</a>. While their severity varies, most women experience them to some degree <a class="yt-timestamp" data-t="02:40:11">[02:40:11]</a>.
*   **Cognitive and Sleep Disturbances** Brain fog and sleep disturbances are also common, with sleep issues potentially exacerbated by hot flashes and night sweats <a class="yt-timestamp" data-t="02:40:27">[02:40:27]</a>.
*   **Sexual Changes** As menopause progresses, women may experience vaginal atrophy, dryness, and a reduction in libido <a class="yt-timestamp" data-t="02:40:50">[02:40:50]</a>. Testosterone plays a role in libido, while estradiol (a form of estrogen) is important for vaginal health <a class="yt-timestamp" data-t="02:40:59">[02:40:59]</a>. Pain during intercourse can also result from these changes <a class="yt-timestamp" data-t="02:41:17">[02:41:17]</a>.
*   **Bone Density Loss** Both men and women reach peak bone density in their early 20s <a class="yt-timestamp" data-t="02:41:37">[02:41:37]</a>. For women, bone mineral density (BMD) declines gradually until menopause, after which there is a sharp and rapid decline <a class="yt-timestamp" data-t="02:41:48">[02:41:48]</a>. This loss significantly increases the risk of falls and fractures later in life, particularly hip or femur fractures, which have severe implications for mortality and morbidity <a class="yt-timestamp" data-t="02:41:58">[02:41:58]</a>. Estrogen is critical for regulating BMD, acting as a chemical signal to promote bone building in response to mechanical force <a class="yt-timestamp" data-t="03:02:25">[03:02:25]</a>.

## Hormone Replacement Therapy (HRT)

The collective symptoms and long-term risks associated with menopause often justify the use of Hormone Replacement Therapy (HRT) <a class="yt-timestamp" data-t="02:42:18">[02:42:18]</a>.

### Misinterpretations of the Women's Health Initiative (WHI) Study

The medical community's approach to HRT was significantly impacted by a misinterpretation of the Women's Health Initiative (WHI) study, first published in 2001-2002 <a class="yt-timestamp" data-t="02:42:42">[02:42:42]</a>. This misinterpretation led to a widespread reduction in HRT prescriptions, with an estimated over 20 million women unnecessarily deprived of hormones <a class="yt-timestamp" data-t="02:43:20">[02:43:20]</a>.

**Key Flaws in the WHI Interpretation:**
*   **Study Design** The WHI study included two main groups: women with a uterus and women without a uterus. Women with a uterus received conjugated equine estrogen (CEE) plus medroxyprogesterone acetate (MPA), while those without a uterus received CEE alone <a class="yt-timestamp" data-t="02:44:28">[02:44:28]</a>. Progesterone was added for women with a uterus to prevent endometrial hyperplasia, a known risk of unopposed estrogen <a class="yt-timestamp" data-t="02:44:50">[02:44:50]</a>.
*   **Patient Demographics** The women in the study were, on average, considerably older, about 7 to 10 years past menopause <a class="yt-timestamp" data-t="02:45:54">[02:45:54]</a>. Many were also relatively unhealthy at baseline <a class="yt-timestamp" data-t="02:50:23">[02:50:23]</a>.
*   **Misleading Headlines** The study was terminated early when the CEE plus MPA group showed a 0.1% higher risk of breast cancer compared to placebo, leading to headlines claiming a "25% increase in breast cancer risk" <a class="yt-timestamp" data-t="02:46:09">[02:46:09]</a>. This was a statistically significant *relative* risk increase (5 cases per 1000 women vs. 4 per 1000), but a clinically insignificant *absolute* risk <a class="yt-timestamp" data-t="02:47:08">[02:47:08]</a>.
*   **No Mortality Difference** Crucially, there was no difference in breast cancer mortality between the groups, a finding that remains true even with 19-year follow-up data <a class="yt-timestamp" data-t="02:47:31">[02:47:31]</a>.
*   **MPA vs. Estrogen** The CEE alone group actually had a *lower* incidence and eventually lower mortality from breast cancer <a class="yt-timestamp" data-t="02:47:55">[02:47:55]</a>. This suggests that the slight increase in breast cancer incidence in the CEE plus MPA group was likely driven by the synthetic progestin (MPA), not the estrogen <a class="yt-timestamp" data-t="02:48:29">[02:48:29]</a>. MPA is largely not used in modern HRT regimens <a class="yt-timestamp" data-t="02:48:48">[02:48:48]</a>.

### Types of Hormones and Administration Methods

Modern HRT focuses on using bioidentical hormones and safer administration methods <a class="yt-timestamp" data-t="02:50:29">[02:50:29]</a>.

#### Estrogen
*   **Types:** Bioidentical estrogens used today are primarily estradiol (E2) and sometimes estriol (E3) <a class="yt-timestamp" data-t="02:50:50">[02:50:50]</a>. Estriol products often need to be compounded <a class="yt-timestamp" data-t="02:51:11">[02:51:11]</a>.
*   **Risk Mitigation:** The risk of breast cancer from estrogen is largely associated with certain metabolites, specifically 4-hydroxyestrone, which is derived from E1 (estrone) but not E3 (estriol) <a class="yt-timestamp" data-t="02:51:57">[02:51:57]</a>.
*   **Administration:**
    *   **Oral Estrogen:** Oral estradiol is generally avoided due to a small, non-zero increase in the risk of hypercoagulability (blood clots), unless a woman's skin does not permit topical absorption <a class="yt-timestamp" data-t="02:52:46">[02:52:46]</a>.
    *   **Estrogen Patch:** Preferred for its consistent, steady-state delivery and easy dose adjustment <a class="yt-timestamp" data-t="02:53:10">[02:53:10]</a>.
    *   **Estrogen Pellets:** Inserted subdermally, but adjusting the dose can take months <a class="yt-timestamp" data-t="02:53:57">[02:53:57]</a>.
    *   **Vaginal Estrogen Creams/Suppositories:** Can be used to address local vaginal symptoms without systemic absorption, but will not provide bone protection or alleviate systemic symptoms like night sweats <a class="yt-timestamp" data-t="02:54:50">[02:54:50]</a>.

#### Progesterone
*   **Purpose:** For women with a uterus, progesterone is essential to oppose estrogen and prevent endometrial hyperplasia <a class="yt-timestamp" data-t="02:44:50">[02:44:50]</a>.
*   **Administration:**
    *   **Oral Micronized Bioidentical Progesterone:** Commonly used at doses typically between 100-200 milligrams to adequately oppose estrogen at the endometrial level <a class="yt-timestamp" data-t="02:49:02">[02:49:02]</a> <a class="yt-timestamp" data-t="02:58:50">[02:58:50]</a>.
    *   **Progesterone-Coated IUD:** An alternative for women who don't benefit symptomatically from oral progesterone or find suppositories inconvenient, providing local protection <a class="yt-timestamp" data-t="02:49:09">[02:49:09]</a>.

#### Testosterone
*   **Importance:** Testosterone is crucial for maintaining muscle mass in women, just as it is for men <a class="yt-timestamp" data-t="03:14:57">[03:14:57]</a>. It is also important for sexual function, including libido, arousal, and orgasmic function <a class="yt-timestamp" data-t="03:14:09">[03:14:09]</a>.
*   **Replacement Strategy:** The goal is to restore women's testosterone levels to those they had in their 30s and 40s, which are very low levels compared to men or bodybuilders <a class="yt-timestamp" data-t="03:15:15">[03:15:15]</a>.
*   **Administration:** Typically about one-tenth the dose men take <a class="yt-timestamp" data-t="03:15:23">[03:15:23]</a>. Intranasal testosterone sprays and intravaginal testosterone are being studied for specific sexual health benefits <a class="yt-timestamp" data-t="03:19:05">[03:19:05]</a>.

### Benefits of HRT
When initiated around the time of menopause, HRT, particularly with bioidentical hormones, offers multiple benefits:
*   **Bone Density** HRT helps prevent the rapid decline in bone mineral density that occurs post-menopause, reducing the risk of osteoporosis and fractures <a class="yt-timestamp" data-t="02:41:53">[02:41:53]</a> <a class="yt-timestamp" data-t="02:58:56">[02:58:56]</a>.
*   **Cardiovascular Health** HRT can reduce the risk of heart disease <a class="yt-timestamp" data-t="03:01:11">[03:01:11]</a>.
*   **Sexual Function** Improves vaginal atrophy, dryness, and can restore libido and orgasmic function <a class="yt-timestamp" data-t="02:40:50">[02:40:50]</a> <a class="yt-timestamp" data-t="03:14:09">[03:14:09]</a>.
*   **Muscle Health** Testosterone, when used in women, can contribute to maintaining muscle mass <a class="yt-timestamp" data-t="03:14:57">[03:14:57]</a>. This aligns with the broader [[influence_of_hormones_and_supplements_on_muscle_health | influence of hormones and supplements on muscle health]].
*   **Cancer Risk** Estrogen appears to be protective or neutral on cancer risk <a class="yt-timestamp" data-t="03:01:19">[03:01:19]</a>.

### Risks and Considerations
While the benefits are significant, especially with appropriate protocols, some considerations exist:
*   **Breast Cancer** The original WHI study suggested a slight increase in breast cancer incidence with CEE plus MPA, but no increase in breast cancer mortality. Modern HRT with bioidentical hormones has not shown an increased risk of breast cancer mortality <a class="yt-timestamp" data-t="02:47:31">[02:47:31]</a> <a class="yt-timestamp" data-t="02:49:52">[02:49:52]</a>.
*   **Blood Clots** Oral estrogen carries a small, non-zero risk of hypercoagulability (blood clots) <a class="yt-timestamp" data-t="02:52:50">[02:52:50]</a>.
*   **Late Initiation** Initiating HRT much later in life (e.g., 10+ years post-menopause) may be counterproductive for Alzheimer's disease risk and could potentially increase it <a class="yt-timestamp" data-t="02:59:14">[02:59:14]</a>. The optimal duration of HRT is still an area of ongoing research, especially regarding outcomes beyond 10-15 years of use <a class="yt-timestamp" data-t="03:01:26">[03:01:26]</a>. However, discontinuing estrogen will lead to a rapid decline in bone density again <a class="yt-timestamp" data-t="03:02:20">[03:02:20]</a>.
*   **Cost** Newer, highly effective, and safe pharmacological interventions like PCSK9 inhibitors and bempedoic acid (which are not directly related to hormones but are mentioned as important drug advancements) can be expensive, often costing around $500 per month <a class="yt-timestamp" data-t="02:23:32">[02:23:32]</a> <a class="yt-timestamp" data-t="02:52:55">[02:52:55]</a>.

### Personalized Approach and Monitoring
A personalized approach is crucial for HRT, avoiding a "paint-by-numbers" method <a class="yt-timestamp" data-t="03:18:18">[03:18:18]</a>.
*   **Monitoring Hormones:** For women in perimenopause, estradiol and FSH levels are monitored, typically around day 5 of the menstrual cycle <a class="yt-timestamp" data-t="02:56:31">[02:56:31]</a>. A rising FSH and declining estradiol indicate approaching menopause <a class="yt-timestamp" data-t="02:56:50">[02:56:50]</a>. In full menopause, the goal is to maintain FSH around 25-35, which corresponds to estradiol levels lower than during pre-menopausal cycles but sufficient for symptom relief and bone preservation <a class="yt-timestamp" data-t="02:58:05">[02:58:05]</a>.
*   **Individualized Treatment:** Treatment typically starts when a woman becomes symptomatic in perimenopause, often with lower doses <a class="yt-timestamp" data-t="02:57:58">[02:57:58]</a>.
*   **ApoE4 Status:** For individuals with an ApoE4 gene (a genetic risk factor for Alzheimer's disease), early initiation of HRT at menopause may be doubly beneficial <a class="yt-timestamp" data-t="02:59:26">[02:59:26]</a>. This highlights the importance of genetic factors in guiding personalized treatment, as discussed in the context of [[role_of_insulin_and_estrogen_in_breast_cancer_development | hormone influence on breast cancer development]].

## Related Considerations
While not directly part of HRT, other lifestyle factors and health considerations are important for overall well-being during and after menopause:
*   **[[the_role_of_diet_and_nutrition_in_aging | Diet and Nutrition]]**
*   **Exercise** Resistance training and impact activities like jump roping are crucial for building and maintaining bone density, especially when combined with adequate [[role_of_vitamin_d_in_health_and_aging | Vitamin D levels]] <a class="yt-timestamp" data-t="03:06:05">[03:06:05]</a> <a class="yt-timestamp" data-t="03:06:09">[03:06:09]</a>.